NEW YORK, April 22, 2020 /PRNewswire/
-- Nanobeak Biotech Inc., a pioneer in mobile,
non-invasive disease detection at the earliest stages, today
announced that Jeremy Barbera, Board member and Chief
Science Officer, has been relieved of his duties and is no
longer associated with the company, as of April 3, 2020. Thomas M. Joyce will
continue as interim CEO. Mr. Joyce has served as Chairman of
the Nanobeak Board of Directors since July 2019 and as Interim CEO of the Company since
October.
Mr. Joyce brings decades of executive leadership experience to
Nanobeak. In addition to sitting on the boards of a number of
private companies, he is currently on the Board of Blackstone
/ GSO Secured Lending fund, a business development company managed
by a Blackstone affiliate. Prior to that, he spent 11 years as
Chairman and CEO of Knight Capital Group. He spent the earlier
part of his career at Merrill Lynch, where he was responsible
for a series of businesses in its global institutional
equity division.
"We are focused on delivering a device that can both save lives
and millions of dollars across healthcare and law
enforcement," said Mr. Joyce. "When completed, the
technology will allow medical professionals to rapidly screen
for stage one cancer using only a patient's breath and provide law
enforcement the ability to determine in real time the presence of
legal and illegal drugs."
The Company recently completed a stage 1 lung cancer clinical
trial at Johns Hopkins University and is currently in the
analysis phase of that study.
About Nanobeak Biotech
Leveraging proven, NASA technology, Nanobeak Biotech, Inc is
focusing on developing mobile, non-invasive drug and disease
detection at the earliest stages. Applications will primarily be in
the life sciences industry around the detection of early stage
cancers and the drug/law enforcement sector.
View original
content:http://www.prnewswire.com/news-releases/nanobeak-announces-termination-of-jeremy-barbera-301045063.html
SOURCE Nanobeak Biotech Inc.